Watch ESLA. Know when insiders buy.
One email the day a filing lands. Free.
ESLA
Estrella Immunopharma, Inc.
0.67
+0.03 +5.49%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $29.3MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$10MNET CASH —52W 0.64 – 3.05SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.1M | −$2.3M | — | -0.05 | −$1.8M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$2.3M | −$2.3M | — | -0.05 | −$6.7M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$613K | −$613K | — | -0.01 | −$177K | — | — | Mar 18 |
| Q3 2025 · Sep 30 | — | — | — | −$4.8M | −$4.8M | — | -0.13 | −$727K | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$5.5M | −$5.5M | — | -0.15 | −$415K | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$2.1M | −$2.1M | — | -0.06 | −$466K | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.1M | −$1.1M | — | -0.03 | −$896K | — | — | Mar 18 |
| Q3 2024 · Sep 30 | — | — | — | −$3.4M | −$3.4M | — | -0.09 | −$2.2M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$3.9M | −$4M | — | -0.11 | −$292K | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$470K | −$470K | — | -0.01 | −$4.2M | — | — | Nov 12 |
| Q4 2023 · Dec 31 | — | — | — | −$1M | −$1M | — | -0.03 | −$11.3M | — | — | May 15 |
| Q3 2023 · Sep 30 | — | — | — | −$1.9M | −$1.9M | — | -1.78 | −$275K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$13.1M | −$13.1M | — | -0.35 | −$1.8M | — | — | — | — |
| FY2024 · to Jun 30 | — | — | −$7.3M | −$7.3M | — | -0.27 | −$16.1M | — | — | — | — |
| FY2023 · to Jun 30 | — | — | −$11.1M | −$11.1M | — | -36.35 | −$1.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$1.6M | −$996K | — | — | −$1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$249K | −$248K | — | — | −$316K | — | — | — | — |
Every number comes from Estrella Immunopharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.